Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.59 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.59 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742164 | 0.82 | MEN1 (0.79) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| SCHEMBL219432 | 0.78 | MEN1 (1.00) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| SCHEMBL2794662 | 0.78 | MEN1 (1.00) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| Fluoride SCHEMBL27959930 | 0.76 | MEN1 (0.96) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| SCHEMBL27485345 | 0.76 | MEN1 (0.96) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL11456225 | 0.76 | MEN1 (0.96) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| Piperazine SCHEMBL28229145 | 0.76 | MEN1 (0.96) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL7006476 | 0.76 | MEN1 (0.96) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| SCHEMBL8963506 | 0.75 | MEN1 (0.62) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| SCHEMBL8963664 | 0.75 | MEN1 (0.56) | MEN1KMT2AOPRD1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286806-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-11-19 | — | — | US | disclosed |
| US-20090286806-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-11-19 | — | — | US | disclosed |
| US-20090286806-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-11-19 | — | — | US | disclosed |
| EP-2007759-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007118323-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118323-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286806-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1G, CACNA1S | MEN1 3151/4885KMT2A 4198/4885CACNA2D1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.